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AbstrAct
Objective
To determine whether primary trabeculectomy or 
primary medical treatment produces better outcomes 
in term of quality of life, clinical effectiveness, 
and safety in patients presenting with advanced 
glaucoma.
Design
Pragmatic multicentre randomised controlled trial.
setting
27 secondary care glaucoma departments in the UK.
ParticiPants
453 adults presenting with newly diagnosed 
advanced open angle glaucoma in at least one eye 
(Hodapp classification) between 3 June 2014 and 31 
May 2017.
interventiOns
Mitomycin C augmented trabeculectomy (n=227) 
and escalating medical management with intraocular 
pressure reducing drops (n=226)
Main OutcOMe Measures
Primary outcome: vision specific quality of life 
measured with Visual Function Questionnaire-25 
(VFQ-25) at 24 months. Secondary outcomes: general 
health status, glaucoma related quality of life, clinical 
effectiveness (intraocular pressure, visual field, visual 
acuity), and safety.
results
At 24 months, the mean VFQ-25 scores in the 
trabeculectomy and medical arms were 85.4 (SD 13.8) 
and 84.5 (16.3), respectively (mean difference 1.06, 
95% confidence interval −1.32 to 3.43; P=0.38). 
Mean intraocular pressure was 12.4 (SD 4.7) mm Hg 
for trabeculectomy and 15.1 (4.8) mm Hg for medical 
management (mean difference −2.8 (−3.8 to −1.7) 
mm Hg; P<0.001). Adverse events occurred in 88 
(39%) patients in the trabeculectomy arm and 100 
(44%) in the medical management arm (relative risk 
0.88, 95% confidence interval 0.66 to 1.17; P=0.37). 
Serious side effects were rare.
cOnclusiOn
Primary trabeculectomy had similar quality of life and 
safety outcomes and achieved a lower intraocular 
pressure compared with primary medication.
trial registratiOn
Health Technology Assessment (NIHR-HTA) Programme 
(project number: 12/35/38). ISRCTN registry: 
ISRCTN56878850.
Introduction
Glaucoma is a chronic progressive eye disease with 
substantial and detrimental effects on many aspects 
of daily living.1 It is the second most common cause of 
irreversible blindness in the UK, North America, and 
Europe.2 3 The number of patients with glaucoma is 
predicted to increase substantially as the result of an 
ageing population.4
Open angle glaucoma initially affects the peripheral 
vision. Severe visual field loss occurs in people with 
advanced open angle glaucoma, which encroaches on 
central vision and eventually reduces visual acuity. 
Severe restriction of the visual field reduces quality 
of life and increases the risk of falls and fractures.1 
People with advanced open angle glaucoma in both 
eyes, even with good visual acuity, may be eligible for 
certification as severely sight impaired.
The primary risk factor for blindness due to glaucoma 
is advanced vision loss at presentation.5 In the UK, 
guidelines from the National Institute for Health 
and Care Excellence (NICE) suggest that patients 
presenting with advanced disease should be offered 
trabeculectomy as a primary intervention but cite 
poor evidence to support this recommendation.6 This 
guidance is generally not followed owing to concerns 
about potential sight threatening surgical complications 
and lack of evidence supporting primary surgery. Most 
patients are treated medically with escalating topical 
drug therapy,7 only undergoing trabeculectomy if 
medical management is not successful. In North 
America, no specific guidance exists for treatment 
of patients with advanced glaucoma at diagnosis.8 9 
In Europe, guidance suggests that glaucoma surgery 
(trabeculectomy) can be offered.10 In the UK, 10-39% of 
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WhAt Is AlreAdy knoWn on thIs topIc
Advanced glaucoma at presentation is the biggest risk factor for lifetime 
blindness
Medical and surgical treatments for glaucoma are commonly used and effective 
at lowering intraocular pressure
Clinicians are reluctant to undertake primary surgery because of concerns about 
surgical complications and lack of evidence
WhAt thIs study Adds
Quality of life after intervention was equivalent between the treatments 
(trabeculectomy and medical treatment) for the period of the study
Trabeculectomy produced greater lowering of intraocular pressure than did 
medical treatment, and this was sustained 
Severe vision loss as a consequence of trabeculectomy surgery did not occur
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patients with glaucoma present with advanced disease 
in at least one eye,11  12 with late presentation being 
associated with socioeconomic deprivation.11 13 14 The 
manage ment of advanced glaucoma is associated with 
significant costs for healthcare systems.15
Effective treatment can control the disease, 
prevent further sight loss, and so prevent blindness. 
Reducing intraocular pressure is the only proven 
effective treatment for glaucoma.16 17 Better control 
of intraocular pressure at the initial stage following 
diagnosis reduces the risk of further progression.18
In a Cochrane systematic review comparing pri-
mary medical treatment and surgical treatment for 
open angle glaucoma, the authors concluded that 
trabeculectomy lowers intraocular pressure more than 
drugs do but also that previous trials excluded patients 
with advanced disease and did not reflect current 
medical and surgical practice.19 They identified 
comparison of current medical options and modern 
trabeculectomy in people with advanced open angle 
glaucoma as a research priority.19 The Public Health 
Outcomes Framework for England 2013-16 has also 
made reducing the number of people living with 
preventable sight loss a priority,20 and identifying the 
most effective treatment for glaucoma is a priority of 
the James Lind Alliance (https://www.jla.nihr.ac.uk/
priority-setting-partnerships/sight-loss-and-vision/
top-10-priorities/glaucoma-top-10.htm).
We carried out a multicentre randomised controlled 
trial comparing primary medical management against 
primary trabeculectomy for people presenting with 
previously untreated advanced open angle glaucoma.
Methods
trial design
The Treatment of Advanced Glaucoma Study (TAGS) 
was a pragmatic, multicentre, randomised unblinded 
controlled trial conducted in 27 centres in the UK. The 
trial design and baseline characteristics are available 
elsewhere.21 22 The trial protocol is available in 
supplementary appendix 1. The study was conducted 
in accordance with good clinical practice guidelines 
and adhered to the tenets of the Declaration of 
Helsinki. An independent data and safety monitoring 
committee appraised adverse events and reported to an 
independent trial steering committee (supplementary 
appendix 2).
Participants
We recruited adults with newly diagnosed advanced 
glaucoma, defined according to the extent of visual field 
loss (Hodapp-Parrish-Anderson classification),23 in 
one or both eyes. The principal inclusion criterion was 
diagnosis of open angle glaucoma (including pigment 
dispersion glaucoma, pseudoexfoliative glaucoma, 
and normal tension glaucoma). We excluded patients 
who were unable to undergo incisional surgery or had 
a high risk of trabeculectomy failure. Supplementary 
table A provides a complete list of inclusion and 
exclusion criteria. All participants provided written 
informed consent before participation.
randomisation and masking
We randomly assigned participants (1:1) to 
trabeculectomy or medical management, using 
a minimisation algorithm based on centre and 
bilaterality of disease. The unit of randomisation 
was the participant (not the eye). For participants in 
whom both eyes were eligible, we selected an index 
eye on the basis of less severe disease according to 
the mean deviation value of the visual field, but both 
eyes would receive the same allocated treatment. 
Randomisation used a remote web based application 
located at the Centre for Healthcare Randomised Trials 
(CHaRT; University of Aberdeen, Aberdeen, UK). All 
participants were started on medical treatment at the 
time of diagnosis. After randomisation, participants 
allocated to trabeculectomy were placed on the surgical 
waiting list and continued medical treatment to lower 
their intraocular pressure until trabeculectomy was 
undertaken. We anticipated that surgery would occur 
within three months of randomisation.
Surgeons and participants could not be masked 
to the allocated procedure because of the nature of 
the interventions. Masking of intraocular pressure 
measurement was achieved through a two observer 
method.21 Visual field assessment was done by an 
independent reading centre masked to treatment 
allocation.
trial interventions
We defined standard trabeculectomy as the fashioning 
of a “guarded fistula.” The surgeon created a small hole 
into the anterior chamber of the eye, covered by a flap 
of partial thickness sclera allowing aqueous humour 
to filter into the subconjunctival space. The exposure 
time and concentration of mitomycin C was left to the 
discretion of the operating surgeon and decided for 
each case. The operation could be performed under 
either local or general anaesthesia. Each operating 
surgeon was a fellowship trained glaucoma specialist 
who had done at least 30 augmented trabeculectomies. 
All potential surgeons completed a surgical technique 
questionnaire to ensure that the recognised standard 
trabeculectomy procedures were followed.24 25 The 
chief investigator reviewed and signed off these 
questionnaires. If trabeculectomy surgery failed to 
control intraocular pressure adequately, medical 
management was started to further lower the 
intraocular pressure.
Participants randomised to medical treatment 
underwent an escalating medical management 
regimen and were treated with a variety of licensed 
glaucoma drugs (eye drops) in accordance with NICE 
guidelines.6 Escalation of medical management was 
based on the judgment of the treating clinician. If 
drops failed to control intraocular pressure adequa-
tely, oral carbonic anhydrase inhibitors could be 
used. If control of intraocular pressure was deemed 
inadequate on maximum medical therapy, augmented 
trabeculectomy was offered. Guidance for target 
intraocular pressure setting was provided by the 
Canadian Glaucoma Society Target IOP workshop 
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algorithm,26 which suggests an intraocular pressure of 
below 15 mm Hg for patients with advanced glaucoma. 
However, this was not proscriptive, and, in keeping 
with the pragmatic nature of the trial, the patient’s 
clinician determined the target intraocular pressure in 
each case.
Outcomes
The primary outcome was health related quality of life 
measured using the Visual Function Questionnaire-25 
(VFQ-25) at 24 months.27 Secondary outcomes included 
patient reported outcomes: the EuroQol Group’s 5 
dimension 5-level health status questionnaire (EQ-
5D-5L),28 the Health Utility Index-mark 3 (HUI-3),29 
the Glaucoma Utility Index (GUI),30 and the patient’s 
experience. For VFQ-25, the range of values is from 0 
for the lowest visual quality of life to 100 for the highest 
visual quality of life. For the EQ-5D and HUI-3, a score 
of 0 is a state equivalent to death and 1 is full health. 
For the GUI, 0 is the worst state in terms of the effects of 
glaucoma and the side effects of treatments and 1 is the 
best possible state. The secondary clinical effectiveness 
outcomes were intraocular pressure, logarithm of 
mean angle of resolution (logMAR) visual acuity, visual 
field mean deviation measured with the Humphrey 
Visual Field Analyzer, need for cataract surgery, pass/
fail of the visual standards for driving (based on the 
Esterman visual field), eligibility for sight impairment 
certification, and the safety of interventions. Adverse 
events were recorded by the local investigators and 
obtained through follow-up questionnaires completed 
by participants. We considered events related to 
participating in the trial or related to glaucoma to be 
adverse events. Supplementary table B lists the study 
outcomes and collection times. All ocular outcomes 
(visual acuity, visual field mean deviation, intraocular 
pressure, medications, need for cataract surgery) and 
ocular safety events are reported for the index eye.
statistical analysis
We needed outcome data on 190 participants in each 
group for 90% power at a two sided 5% significance 
level to detect a difference in means of 0.33 of a standard 
deviation. This translated to a 6 point difference on 
the VFQ-25, assuming a common standard deviation 
of 18 points.31 We planned to randomise 440 patients 
to allow for a 13.5% (59/440) attrition rate. The study 
followed a pre-specified statistical analysis plan 
(supplementary appendix 3). Our analysis was based 
on the intention to treat (that is, analyse as randomised) 
principle. Statistical significance was at the two sided 
5% level with corresponding confidence intervals 
derived. We used mean (SD) for continuous data and 
frequencies and percentages for categorical variables 
to summarise baseline and follow-up data. To analyse 
our primary outcome, we used a heteroscedastic 
partially nested repeated measures mixed effects linear 
model,32 correcting for baseline VFQ-25 and bilateral 
disease severity and including a random effect for 
surgeon by using restricted maximum likelihood. 
For missing baseline data, the centre specific mean 
was imputed. To estimate the treatment effect for 
adherence to allocated treatment, we used both per 
protocol analysis and complier average causal effect 
methods using instrumental variable regression.33 We 
analysed continuous secondary outcomes by using 
the same modelling approach. Intraocular pressure, 
logMAR visual acuity, and visual field mean deviation 
were analysed for the index eye. For GUI, we updated 
the scoring algorithm to reflect the characteristics of 
trial participants by using a discrete choice experiment 
administered as part of the TAGS study. For the 
patient’s experience, we used a repeated measure 
mixed effects Poisson model adjusting for bilateral 
disease and including a random effect for surgeon. 
For need for cataract surgery, visual standards for 
driving, and overall safety, we used a Poisson model 
adjusting for bilateral disease and including a random 
effect for surgeon to estimate relative risk. For adverse 
events and serious adverse events, we used a Poisson 
model adjusting for bilateral disease. For certification 
as sight impaired, we used Fisher’s exact test to 
compare groups. All estimates are presented with 
95% confidence intervals. For the primary outcome, 
we did pre-specified subgroup analysis on variables 
shown in supplementary figure A, using a stricter level 
of statistical significance (two sided 1% significance 
level) and 99% confidence intervals. We used Stata 
version 16 software for all analyses.
Patient and public participation
We conducted a patient focus group exercise to inform 
willingness of patients to participate in the trial and 
to identify potential barriers to participation, the 
results of which we used to inform study design.34 
Two lay members were involved in study oversight, 
one a glaucoma patient and the second a member of 
a glaucoma charity. One was a member of the Trial 
Steering Committee and the other a member of the 
Project Management Group. The lay members reviewed 
and approved all patient facing material for the trial, 
including the discrete choice experiment, before it was 
distributed to participants.
results
Between 3 June 2014 and 31 May 2017, 453 
participants from 27 hospitals were allocated to either 
trabeculectomy (n=227) or medical management 
(n=226) (fig 1). In the trabeculectomy arm, 201/227 
(89%) participants received trabeculectomy on their 
index eye. For the remaining 26 participants, four had 
surgery in their non-index eye, 16 declined surgery, 
two died before surgery, and four had yet to receive 
surgery. All participants in the medical management 
group received their allocated treatment, and 39/226 
(17%) went on to receive trabeculectomy within two 
years.
For those recruited to the study, the mean age of 
participants was 67.6 (SD 12.3) years and 303/453 
(67%) participants were male. For those who were 
eligible but declined to participate in the trial (n=276), 
the mean age was slightly higher at 69.6 (12.8) years 
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(P=0.04) and 165 (60%) were male (P=0.17). The 
study arms were balanced at baseline (table 1). The 
mean VFQ-25 scores were 87.1 (SD 13.6) and 87.1 
(13.4) in the trabeculectomy and medical management 
arms, respectively. Forty four participants in each arm 
had advanced glaucoma in both eyes.
At 24 months, the mean VFQ-25 scores were 85.4 
(13.8) and 84.5 (16.3) in the trabeculectomy and 
medical management arms, respectively. The mean 
difference was 1.06 (95% confidence interval −1.32 to 
3.43; P=0.38) (table 2). The per protocol and complier 
average causal effect estimates for VFQ-25 were 
similar. We also found no evidence of any differences 
between the pre-specified subgroups (supplementary 
figure A) or for EQ-5D-5L, HUI-3, and GUI at 24 months 
(table 2; fig 2).
The mean intraocular pressure at 24 months was 
12.4 (SD 4.7) mm Hg for the trabeculectomy arm and 
15.1 (4.8) mm Hg for the medical management arm 
(mean difference −2.75 (95% confidence interval 
−3.84 to −1.66) mm Hg; P<0.001) (table 2; fig 3). 
The logMAR visual acuity was higher (worse) in the 
trabeculectomy arm (mean difference 0.07, 0.02 to 
0.11; P=0.006) (table 2). We found no evidence of a 
difference in visual field mean deviation at 24 months 
(mean difference 0.18 (−0.58 to 0.94) dB; P=0.65) or 
other secondary outcomes (table 2).
In total, 88/227 (39%) participants in the 
trabeculectomy arm and 100/226 (44%) in the medical 
management arm had a safety event during the 24 
month follow-up (relative risk 0.88, 95% confidence 
interval 0.66 to 1.17; P=0.37) (table 3). Twelve (5%) 
of 227 participants in the trabeculectomy arm and 
8/226 (4%) in the medical management arm had a 
serious adverse event (relative risk 1.50, 0.62 to 3.66; 
P=0.38). Eighty four (38%) of 222 participants in the 
trabeculectomy arm and 93/221 (42%) in the medical 
management arm had an adverse event (relative risk 
0.90, 0.67 to 1.21; P=0.48). Nine deaths occurred, 
all unrelated to the trial. Two participants developed 
endophthalmitis, one in each arm of the study, and 
three lost more than 10 letters of logMAR visual 
acuity, all in the trabeculectomy group, two owing to 
progressive glaucoma and one owing to central serous 
retinopathy.
The need for additional interventions was greater 
in the trabeculectomy arm. All glaucoma surgery 
related serious adverse events (flat anterior chamber, 
ocular perforation during anaesthesia, diplopia, and 
bleb related endophthalmitis) needed further surgical 
intervention. Of the adverse events reported, 27 
patients needed a further intervention to manage them, 
24 in the trabeculectomy arm and three in the medical 
management arm. At 24 months, fewer participants 
were receiving topical drugs (53/211; 25%) in the 
trabeculectomy arm than in the medical management 
arm (163/208; 78%) (supplementary table C).
discussion
At 24 months, we found no difference between 
treatment arms in the primary outcome, VFQ-25 score, 
which is an established method of assessing glaucoma 
related quality of life.35 36 This was also the case for 
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Fig 1 | trial consort diagram
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characteristics trabeculectomy (n=227) Medical management (n=226)
Mean (SD) age, years 67 (12.2) 68 (12.4)
Male sex 156 (69) 147 (65)
Ethnicity:
 White 182 (80) 191 (85)
 Afro-Caribbean 32 (14) 27 (12)
 Asian—India/Pakistan/Bangladesh 8 (4) 4 (2)
 Asian—Oriental 2 (1) 0 (0)
 Mixed heritage 0 (0) 1 (<1)
 Other 3 (1) 2 (1)
 Missing 0 (0) 1 (<1)
Advanced glaucoma in both eyes 44 (19) 44 (19)
Glaucoma in both eyes 178 (78) 169 (75)
Eligible to be registered as sight impaired:
 No 214 (94) 212 (94)
 Sight impaired 10 (4) 12 (5)
 Severely sight impaired 3 (1) 2 (1)
Glaucoma diagnosis:
 Primary OAG (including NTG) 219 (96) 220 (97)
 Pigment dispersion syndrome 5 (2) 4 (2)
 Psuedoexfoliation syndrome 3 (1) 2 (1)
Diamox* 6 (3) 2 (1)
Family history of glaucoma:
 Yes 63 (28) 79 (35)
 No 152 (67) 131 (58)
 Missing 12 (5) 16 (7)
Median (IQR) No of times visited optician in previous 10 years 5 (2-6); n=214 5 (3-8); n=209
Index of multiple deprivation:
 1st fifth (most deprived) 54 (24) 52 (23)
 2nd fifth 30 (13) 37 (16)
 3rd fifth 45 (20) 43 (19)
 4th fifth 50 (22) 43 (19)
 5th fifth (least deprived) 47 (21) 49 (22)
 Missing 1 (<1) 2 (1)
Mean (SD) VFQ-25 score 87.1 (13.6); n=226 87.1 (13.4); n=224
Mean (SD) VFQ-25 subscale scores:
 Near activities 84.2 (18.5); n=225 84.4 (16.9); n=224
 Distance activities 88.5 (16.1); n=226 89.7 (14.4); n=224
 Dependency 94.0 (17.3); n=226 94.9 (15.7); n=222
 Driving 85.9 (26.7); n=171 84.8 (26.2); n=158
 General health 63.6 (23.4); n=225 60.9 (22.6); n=223
 Role difficulties 87.1 (19.8); n=226 87.4 (20.8); n=222
 Mental health 81.1 (21.2); n=226 81.8 (19.9); n=224
 General vision 74.9 (14.5); n=223 72.8 (14.2); n=223
 Social function 95.2 (11.9); n=225 94.9 (12.1); n=224
 Colour vision 96.9 (10.9); n=223 96.6 (11.1); n=222
 Peripheral vision 86.6 (20.8); n=224 87.2 (20.2); n=224
 Ocular pain 84.7 (19.0); n=225 83.9 (17.2); n=224
Mean (SD) EQ-5D-5L score 0.844 (0.185); n=222 0.837 (0.176); n=222
Mean (SD) HUI-3 score 0.814 (0.202); n=214 0.809 (0.208); n=214
Mean (SD) GUI score 0.884 (0.131); n=219 0.863 (0.130); n=222
Participant’s experience (glaucoma getting worse):
 Yes 95 (42) 76 (34)
 No 113 (50) 133 (59)
 Missing 19 (8) 17 (8)
Visual standards for driving:
 Pass 187 (82) 196 (87)
 Fail 27 (12) 21 (9)
 Missing 13 (6) 9 (4)
Mean (SD) VFMD for better eye, dB −5.48 (6.37) −5.49 (5.91); n=224
Mean (SD) VFMD for worse eye, dB −15.53 (6.88) −15.89 (6.57)
Mean (SD) VFMD for non-index eye, dB −6.1 (7.7) −6.1 (7.1)
baseline characteristics for index eye only
Lens status:
 Phakic 212 (93) 209 (92)
 Pseudophakic 15 (7) 17 (8)
Mean (SD) central corneal thickness, µm 539.4 (35.7); n=226 541.4 (35.7); n=223
table 1 | baseline characteristics. values are numbers (percentages) unless stated otherwise
(Continued)
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outcomes. Compared with baseline, surgery was more 
effective in lowering intraocular pressure at all time 
points measured, and the trabeculectomy arm required 
far fewer topical medications for control of intraocular 
pressure. Adverse events were similar between arms.
comparison with other studies
For patients, maintaining their quality of life and 
independence is the most important outcome from their 
glaucoma management.37 38 Both eyes contribute to 
vision related quality of life, so this reflects the true visual 
experience of patients and reports the visual outcomes 
they achieve. The use of a patient reported outcome 
measure as the primary outcome reflects this importance 
and is consistent with the use of health related quality 
of life outcomes as primary outcomes in two previous 
recently published NIHR funded randomised controlled 
trials—Effectiveness in Angle Closure Glaucoma of Lens 
Extraction Study (EAGLE)39 and the Lasers in Glaucoma 
and Ocular Hypertension Trial (LiGHT).40
We observed a clear reduction in intraocular 
pressure in both study arms for the duration of the 
study from similar baseline pressures. This was greater 
in the trabeculectomy arm, where we saw a reduction 
to 12.4 (SD 5.7) mm Hg at four months, and it remained 
at around 12 mm Hg for the remainder of the study. 
For the duration of the study, a 3-4 mm Hg additional 
reduction in intraocular pressure was achieved in the 
trabeculectomy arm. This is a clinically important 
difference likely to result in better preservation of 
visual field over a patient’s lifetime. A sustained 
reduction in intraocular pressure is recognised to be 
the most effective method of preventing further visual 
field loss in glaucoma.17 18 41
At 24 months, the modest deterioration in visual 
acuity is potentially due to the development of early 
cataract in the trabeculectomy arm42 43; although this 
was statistically significant, it may not be clinically 
significant as it corresponds to a reduction of only 2.5 
letters of logMAR visual acuity,44 and quality of life 
and requirement for cataract surgery were very similar 
in both arms at 24 months. We found no substantive 
difference between arms for the other main measure 
of visual function and disease progression, the visual 
field test.
A major concern for clinicians was the perceived 
“high risk” of complications associated with 
trabeculectomy.7 The overall frequency of adverse 
events was broadly similar between the treatment 
arms. Two specific concerns of clinicians related 
to trabeculectomy were risk of blindness from bleb 
related endophthalmitis and risk of unexplained 
visual loss (“wipe-out”) immediately after surgery. No 
unexplained loss of vision occurred immediately after 
surgery, indicating no occurrence of wipe-out. The 
perceived risk of wipe-out is not supported by current 
evidence. Two patients developed endophthalmitis, 
one in each arm. One occurred in a participant 
originally allocated to the medical management 
arm who subsequently had a trabeculectomy for 
uncontrolled intraocular pressure. The other was an 
endogenous endophthalmitis related to a diabetic foot 
ulcer in a patient allocated to the trabeculectomy arm. 
Both were treated with intravitreal antibiotics and had 
good visual recovery.
All serious adverse events related to glaucoma 
surgery (flat anterior chamber, ocular perforation 
during anaesthesia, diplopia, and bleb related 
endophthalmitis) required further surgical interven-
tion. Of the adverse events reported, 27 patients 
needed further intervention to manage them, 24 in 
the trabeculectomy arm and three in the medical 
management arm. All adverse events were managed 
successfully and no patients had any permanent vision 
characteristics trabeculectomy (n=227) Medical management (n=226)
Glaucoma drops:
 Prostaglandin analogue 186 (82) 182 (81)
 β blocker 52 (23) 52 (23)
 Carbonic anhydrase inhibitor 45 (20) 33 (15)
 α agonist 7 (3) 4 (2)
Diamox* 6 (3) 2 (1)
Ocular comorbidity 50 (22) 50 (22)
Ocular comorbidity details†:
 Age related macular degeneration 6 (12) 4 (8)
 Cataract 42 (84) 42 (84)
 Vascular occlusion 2 (4) 1 (2)
 Diabetic retinopathy 1 (2) 1 (2)
 Other 9 (18) 6 (12)
Mean (SD) VFMD, dB −14.91 (6.36) −15.26 (6.34)
Mean (SD) logMAR visual acuity 0.15 (0.25) 0.17 (0.26); n=223
Mean (SD) intraocular pressure, mm Hg:
 Diagnosis 26.9 (9.1); n=226 25.9 (8.4); n=223
 Baseline 19.4 (6.2); n=222 19.0 (5.7); n=221
EQ-5D-5L=EuroQol Group’s 5 dimension 5-level health status questionnaire; GUI=Glaucoma Utility Index; HUI-3=Health Utility Index-mark 3; 
IQR=interquartile range; logMAR=logarithm of mean angle of resolution; NTG=normal tension glaucoma; OAG=open angle glaucoma; VFMD=visual field 
mean deviation; VFQ-25=National Eye Institute Visual Function Questionnaire (25 items).
For VFQ-25, values range from 0 for lowest visual quality of life to 100 for highest visual quality of life. For EQ-5D and HUI-3, score of 0 is state equivalent 
to death and 1 is full health. For GUI, 0 is worst state in terms of effects of glaucoma and side effects of treatments and 1 is best possible state.
*Taken orally.
†Participants can have more than one.
table 1 | continued
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table 2 | Primary and secondary outcomes. values are mean (sD) unless stated otherwise
Outcomes trabeculectomy (n=227) Medical management (n=226) Mean difference* (95% ci) P value
VFQ-25:
 Baseline 87.1 (13.6); n=226 87.1 (13.4); n=224 - -
 4 months 85.1 (14.9); n=212 86.5 (13.6); n=216 −1.24 (−3.58 to 1.11) 0.30
 12 months 85.4 (14.3); n=214 86.3 (13.1); n=209 −0.64 (−3.00 to 1.72) 0.60
 24 months 85.4 (13.8); n=207 84.5 (16.3); n=205 1.06 (−1.32 to 3.43) 0.383
EQ-5D-5L:
 Baseline 0.844 (0.185); n=222 0.837 (0.176); n=222 - -
 1 month 0.838 (0.185); n=194 0.808 (0.203); n=203 0.025 (−0.012 to 0.062) 0.19
 3 months 0.836 (0.167); n=186 0.814 (0.195); n=179 0.015 (−0.024 to 0.053) 0.46
 6 months 0.850 (0.184); n=186 0.822 (0.204); n=195 0.016 (−0.021 to 0.054) 0.39
 12 months 0.837 (0.177); n=211 0.823 (0.164); n=209 0.014 (−0.022 to 0.051) 0.44
 18 months 0.828 (0.185); n=181 0.791 (0.219); n=184 0.023 (−0.016 to 0.061) 0.24
 24 months 0.810 (0.179); n=206 0.796 (0.191); n=203 0.016 (−0.021 to 0.053) 0.41
HUI-3:
 Baseline 0.814 (0.202); n=214 0.809 (0.208); n=214 - -
 1 month 0.791 (0.232); n=184 0.786 (0.230); n=193 −0.000 (−0.043 to 0.043) 1.00
 3 months 0.796 (0.223); n=180 0.779 (0.222); n=179 0.007 (−0.036 to 0.051) 0.74
 6 months 0.805 (0.216); n=180 0.782 (0.224); n=182 0.020 (−0.024 to 0.063) 0.38
 12 months 0.829 (0.193); n=204 0.798 (0.199); n=196 0.024 (−0.018 to 0.066) 0.26
 18 months 0.802 (0.212); n=169 0.749 (0.258); n=174 0.022 (−0.022 to 0.066) 0.32
 24 months 0.786 (0.227); n=198 0.751 (0.246); n=193 0.036 (−0.006 to 0.078) 0.09
GUI:
 Baseline 0.884 (0.131); n=219 0.863 (0.130); n=222 - -
 1 month 0.862 (0.138); n=194 0.853 (0.156); n=205 −0.000 (−0.028 to 0.028) 0.98
 3 months 0.849 (0.130); n=187 0.844 (0.156); n=190 −0.008 (−0.036 to 0.021) 0.59
 6 months 0.839 (0.159); n=186 0.853 (0.135); n=191 −0.024 (−0.052 to 0.005) 0.11
 12 months 0.857 (0.139); n=209 0.860 (0.143); n=204 −0.012 (−0.039 to 0.016) 0.40
 18 months 0.851 (0.144); n=181 0.832 (0.157); n=184 0.003 (−0.026 to 0.032) 0.83
 24 months 0.849 (0.152); n=205 0.830 (0.184); n=202 0.011 (−0.017 to 0.039) 0.43
Patient’s experience  
(glaucoma getting worse)—No (%):
 Baseline 95/208 (46) 76/209 (36) - -
 1 month 60/188 (32) 50/201 (25) 1.19 (0.79 to 1.80) 0.39
 3 months 37/182 (20) 40/185 (22) 0.88 (0.55 to 1.41) 0.59
 6 months 30/182 (16) 40/149 (20) 0.74 (0.45 to 1.21) 0.23
 12 months 38/207 (18) 57/199 (29) 0.59 (0.38 to 0.91) 0.02
 18 months 40/180 (22) 38/181 (21) 0.99 (0.62 to 1.59) 0.98
 24 months 44/196 (22) 57/194 (29) 0.70 (0.46 to 1.07) 0.10
Intraocular pressure, mm Hg†:
 Baseline 19.4 (6.15); n=222 19.05 (5.73); n=221 - -
 4 months 12.4 (5.73); n=217 16.40 (4.12); n=220 −4.11 (−5.18 to −3.05) <0.001
 12 months 11.9 (4.48); n=215 16.12 (4.54); n=209 −4.25 (−5.33 to −3.18) <0.001
 24 months 12.4 (4.71); n=206 15.07 (4.80); n=202 −2.75 (−3.84 to −1.66) <0.001
LogMAR visual acuity†:
 Baseline 0.15 (0.25); n=227 0.17 (0.26); n=223 - -
 4 months 0.25 (0.31); n=210 0.16 (0.24); n=217 0.10 (0.05 to 0.14) <0.001
 12 months 0.18 (0.23); n=212 0.16 (0.26); n=209 0.03 (−0.02 to 0.08) 0.20
 24 months 0.21 (0.28); n=199 0.16 (0.26); n=201 0.07 (0.02 to 0.11) 0.006
Visual fields mean deviation, dB†:
 Baseline −14.91 (6.36); n=227 −15.26 (6.34); n=226 - -
 4 months −14.35 (6.78); n=211 −14.84 (6.52); n=217 −0.05 (−0.79 to 0.70) 0.907
 12 months −14.76 (6.92); n=214 −14.95 (6.53); n=209 0.03 (−0.72 to 0.78) 0.94
 24 months −15.15 (6.63); n=202 −15.42 (6.39); n=200 0.18 (−0.58 to 0.94) 0.65
Need for cataract surgery—No (%) 28/222 (13) 27/221 (12) 0.98 (0.50 to 1.95) 0.96
Visual standards for driving  
(pass/no defects)—No (%):
 Baseline 187/214 (87) 196/217 (90) - -
 24 months 167/187 (89) 168/188 (89) 1.01 (0.81 to 1.25) 0.95
Registered as sight impaired  
at 24 months—No (%):
 No 182/186 (98) 184/184 (100) - 0.12
 Sight impaired 4/186 (2) 0/184 (0) - -
EQ-5D-5L=EuroQol Group’s 5 dimension 5-level health status questionnaire; GUI=Glaucoma Utility Index; HUI-3=Health Utility Index-mark 3; logMAR; logarithm of mean angle of resolution; VFQ-
25=National Eye Institute Visual Function Questionnaire (25 items); VFMD=visual field mean deviation.
For VFQ-25, values range from 0 for lowest visual quality of life to 100 for highest visual quality of life. For EQ-5D and HUI-3, score of 0 is state equivalent to death and 1 is full health. For GUI, 0 
is worst state in terms of effects of glaucoma and side effects of treatments and 1 is best possible state.
*Mean difference for continuous variables and risk ratios for dichotomous variables.
†Index eye only.
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loss associated with these adverse events. However, 
both clinicians and patients must be aware of the 
possibility of additional interventions being needed if 
the patient has trabeculectomy.
strengths and limitations of study
We adopted a pragmatic approach to replicate current 
clinical practice in the management of advanced 
glaucoma as closely as possible. The inclusion of 
multiple centres and multiple surgeons undertaking 
standard trabeculectomy, along with the use of 
available topical medications, ensured that this study 
was representative of the current standard of care.6 8-10 
Both of the interventions used in TAGS are used 
routinely worldwide to lower intraocular pressure.6 8-10 
Potential participants in TAGS were excluded if they 
were deemed to be at high risk of trabeculectomy 
failure, as alternative surgical interventions are consi-
dered superior in these situations45; this is consistent 
with standard care in the UK. Large sample size, low 
attrition rate, involvement of multiple centres, the 
randomisation process, and masking for clinical 
assessments for intraocular pressure and visual fields 
minimised potential risk of bias.
Limitations include the fact that treatments and 
patient reported outcome measures could not be 
masked from participants or clinicians. Although 
the design of the trial was pragmatic, completion of 
questionnaires would not be part of standard care. This 
may have affected participants’ feeling of wellbeing 
either in a negative way owing to the burden of 
completion or in a positive way owing to the perception 
that they were being well cared for. However, no 
evidence exists of either a positive or negative effect. 
Rates of return and completion of questionnaires did 
not differ between study arms. In this study, most 
participants were white, which reflects the population 
of the UK; this may, however, limit the generalisability 
of our findings to non-white populations.
conclusions
In conclusion, TAGS showed no difference in quality 
of life between treatment arms. Surgery was safe and 























































































Fig 2 | Mean national eye institute visual Function Questionnaire (25 items) (vFQ-25), euroQol group’s 5 dimension 5-level health status 
questionnaire (eQ-5D-5l), Health utility index-mark 3 (Hui-3), and glaucoma utility index (gui) scores. For vFQ-25, range of values is from 0 for 
lowest visual quality of life to 100 for highest visual quality of life. For eQ-5D and Hui-3, score of 0 is state equivalent to death and 1 is full health. 
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Fig 3 | Mean (95% ci) intraocular pressure (iOP) for index eye by group over time
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pressure compared with primary medication. This 
study provides the first direct evidence of the outcomes 
of interventions for patients presenting with advanced 
glaucoma. These results will inform clinicians and 
patients in making treatment choices.
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Medical management  
(n=226)
No of participants with safety event 88 (39) 100 (44)
serious adverse events
No of participants 12/226 (5) 8/226 (4)
No of events 13 8
Details:
 Death 5 4
 Life threatening 0 1
 Hospital admission 3 4
 Significant disability 2 0
 Important condition 3 1
 Expected event 3 2
Classification:
 General medical (death) 2 4
 Unclassified (death) 3 0
 General medical 2 3
 Related to glaucoma surgery 3 1
 General ophthalmology 1 0
 Non-glaucoma vision loss 1 0
 Glaucoma progression despite treatment 1 0
adverse events
No of participants 84/222 (38) 93/221 (42)
No of events 139 155
Details:
 Drop related* 18 83
 Ocular surface related† 29 37
 Non-specific‡ 19 17
 Early bleb leak 12 3
 Hypotony (<6 mm Hg) requiring intervention 11 3
 Choroidal effusion 9 2
 Shallow anterior chamber 7 2
 Ptosis 5 1
 Hyphema 4 0
 Late bleb leak 4 0
 Potential adverse event related to surgery 3 1
 Cataract 1 2
 Conjunctival buttonhole 3 0
 Corneal epithelial defect 3 0
 Glaucoma progression 1 2
 Irreversible loss of ≥10 ETDRS letters§ 3 0
 Blebitis 2 0
 Suprachoroidal haemorrhage 2 0
 Endophthalmitis§—endogenous 1 0
 Endophthalmitis§—bleb related 0 1
 Persistent uveitis 1 0
 Macular oedema 0 1
 Non-specific unrelated uveitis 1 0
ETDRS=Early Diabetic Treatment Diabetic Retinopathy Study.
*Includes drop allergy, drop intolerance, periorbital skin pigmentation, taste disturbance.
†Includes dry eye, blepharitis, meibomitis, corneal epitheliopathy, conjunctivitis, itchy eye, watering eyes.
‡Non-specific blurred vision, retinal vascular occlusion, vitreomacular traction, chalazion, subconjunctival 
haemorrhage.
§Also recorded as a serious adverse event.
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